Generic Biologics & FDA: "No Recourse" But To Develop Guidance, Crawford Says

The acting FDA director tells a Senate appropriations hearing that "as the science improves," FDA needs to consider the regulatory implications. Subcommittee Chairman Bennett (R-Utah) presses for more transparency as the agency develops its policy.